Alteron Therapeutics

Executive Summary

Alteron Therapeutics is a private biopharmaceutical company dedicated to developing small molecule therapies for devastating neurodegenerative diseases and cystic fibrosis. Founded in 2017 and headquartered in Kalamazoo, Michigan, the company addresses critical unmet needs in ALS, Alzheimer's disease, frontotemporal lobar degeneration, and cystic fibrosis—conditions that currently lack effective disease-modifying treatments. While still operating at an early stage, Alteron leverages a small molecule platform to target key pathological mechanisms shared across these disorders, with the goal of slowing or halting disease progression. The company's pipeline is preclinical, and there is no publicly available information on specific drug candidates or clinical trial activity. Given the high-risk nature of early-stage drug development and the competitive landscape, Alteron's potential hinges on successful advancement of its lead programs into clinical trials and securing partnerships or funding to support further development.

Upcoming Catalysts (preview)

• Q4 2026Preclinical data presentation for lead candidate in ALS or Alzheimer's30% success
• Q1 2027IND filing for first therapeutic program25% success
• Q2 2027Series A financing round or strategic partnership40% success